Sustained drug delivery optimizes long-term treatment of patients with schizophrenia

Acta Neuropsychiatrica

Volumn 16, Issue 6, 2004, Pages 319-325

  Chue, Pierre S ^a,d   D'Hoore, Peter ^b   Ramstack, J Michael ^c  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c ALKERMES INC   (United States)

^d NONE   (Canada)

Author keywords

Antipsychotic; Compliance; Long acting; Maintenance; Tolerability

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CONSTA; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZUCLOPENTHIXOL;

ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SOLUTION; DRUG TOLERABILITY; EDEMA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INJECTION SITE REACTION; LONG TERM CARE; META ANALYSIS; PAIN; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; RELAPSE; REMISSION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUSTAINED DRUG RELEASE; VISUAL ANALOG SCALE;

EID: 22344452613     PISSN: 09242708     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0924-2708.2004.00100.x     Document Type: Article

References (56)

1. KANE JM, AGUGLIA E, ALTAMURA AC et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 1998;8:55-66.
2. LIBERMAN R, KOPELOWICZ A. Recovery from schizophrenia: a challenge for the 21st century. Int Rev Psychiatry 2002;14:245-255.
3. LIBERMAN R, WALLACE C, BLACKWELL G, ECKMAN T, VACCARO J, KUEHNEL T. Innovations in skills training for the seriously mentally ill: the UCLA Social & Independent Living Skills modules. Innovat Res 1993;2:43-60.
4. JOHNSON D. Depot neuroleptics. In: Barnes T (ed). Antipsychotic drugs and their side-effects. London: Academic Press, 1993: 205-212.
5. ROBINSON D, WOERNER MG, ALVIR JM et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-247.
6. JOHNSON DA, PASTERSKI G, LUDLOW JM, STREET K, TAYLOR RD. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand 1983;67:339-352.
7. KANE JM. Schizophrenia. N Eng J Med 1996;334:34-41.
8. KISSLING W. The current unsatisfactory state of relapse prevention in schizophrenic psychoses - suggestions for improvement. Clin Neuropharmacol 1991;14(Suppl. 2): S33-S44.
9. AYUSO-GUTIERREZ JL, DEL RIO VEGA JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 1997;28:199-206.
10. AMERICAN PSYCHIATRIC ASSOCIATION. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154(Suppl. 4):1-63.
11. MCEVOY J, SCHEIFLER P, FRANCES A. Expert consensus guideline series. Treatment of schizophrenia. J Clin Psychiatry 1999;60(Suppl. 11):1-80.
12. MISDRAHI D, LLORCA PM, LANCON C, BAYLE FJ. Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications. Encephale 2002;28(3 Part 1):266-272.
13. BUCHANAN A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992;22:787-797.
14. FLEISCHHACKER WW, MEISE U, GUENTHER V, KURZ M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand Suppl 1994;89(Suppl. 382):11-15.
15. WEIDEN P, AQUILA R, STANDARD J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996;57(Suppl. 11):53-60.
16. DAVIS JM, MATALON L, WATANABE MD, BLAKE L, METALON L. Depot antipsychotic drugs. Place in therapy. Drugs 1994;47:741-773.
17. PERKINS DO. Adherence to antipsychotic medications. J Clin Psychiatry 1999;60(Suppl. 21):25-30.
18. KANE JM. Problems of compliance in the outpatient treatment of schizophrenia. J Clin Psychiatry 1983;44:3-6.
19. DOCHERTY JP, KOZMA C, GROGG A, LASSER R. Antipsychotic maintenance in schizophrenia: partial compliance and clinical outcome. American College of Neuropsychopharmacology scientific abstracts, American College of Neuropsychopharmacology 41st Annual Meeting, December 8-12, 2002, San Juan, Puerto Rico: 179, Abstract 154.
20. VALENSTEIN M, COPELAND LA, BLOW FC et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002;40:630-639.
21. KOZMA C, GROGG A. Medication compliance and hospitlaization in schizophrenia. Presented at the 6th meeting of the College of Psychiatric and Neurologic Pharmacists, 1-4 May, 2003 Poster Abstracts pp10.
22. LOVE R. Strategies for increasing treatment compliance: the role of long-acting antipsychotics. Am J Health Syst Pharm 2002;59(Suppl. 8):S10-S15.
23. GERLACH J. Oral versus depot administration of neuroleptics in relapse prevention. Acta Psychiatr Scand Suppl 1994;382:S28-S32.
24. YOUNG JL, ZONANA HV, SHEPLER L. Medication non-compliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 1986;14:105-122.
25. CRAMER JA, ROSENHECK R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196-201.
26. GREENBERG RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984;6:592-599.
27. HALDOL. Summary of Product Characteristics, 2001.
28. FLUPHENAZINE. British Notary Fomulary; accessed May 2003.
29. REMINGTON GJ, ADAMS ME. Depot neuroleptic therapy: clinical considerations. Can J Psychiatry 1995;40(3 Suppl. 1):S5-S11.
30. JACOBSSON L, ODLING H. Psykologiska aspekter po depabehandling vid schizofrena syndrom. Lakartidningen 1980;77:3522-3526.
31. WALBURN J, GRAY R, GOURNAY K, QURAISHI S, DAVID AS. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001;179:300-307.
32. WISTEDT B. How does the psychiatric patient feel about depot treatment, compulsion or help. Nord J Psychiatry 1995;49(Suppl. 35):41-46.
33. BLOCH Y, MENDLOVIC S, STRUPINSKY S, ALTSHULER A, FENNIG S, RATZONI G. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry 2001;62:855-859.
34. HAMANN GL, EGAN TM, WELLS BG, GRIMMIG JE. Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/mL. J Clin Psychiatry 1990;51:502-504.
35. BUCHANAN R. Clozapine: efficacy and safety. Schizophr Bull 1995;21:579-591.
36. TOLLEFSON GD, BEASLEY CM JR, TRAN PV et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-165.
37. KENNEDY E, SONG F, HUNTER R, CLARKE A, GILBODY S. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2000;(2):CD000440.
38. VORUGANTI L, CORTESE L, OYEWUMI L, CERNOVSKY Z, ZIRUL S, AWAD A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizo Res 2000;43:135-145.
39. WAHLBECK K, CHEINE M, ESSALI MA. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2000;2:CD000059.
40. CSERNANSKY JG, MAHMOUD R, BRENNER R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Eng J Med 2002;346:16-22.
41. DAVIS J, CHEN N. Clinical profile of an atypical anti-psychotic: risperidone. Schizophr Bull 2002;28:43-61.
42. CSERNANSKY JG, SCHUCHART EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002;16:473-484.
43. GLICK I, DAVIS JNC. A meta-analysis of the efficacy of second-generation antipsychotics. Schizophr Res 2003;60(1 Suppl):285.
44. SRISURAPANONT M, DISAYAVANISH C, TAIMKAEW K. Quetiapine for schizophrenia. Cochrane Database Syst Rev 2000;3:CD000967.
45. HIRSCH SR, KISSLING W, BAUML J, POWER A, O'CONNOR R. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002;63:516-523.
46. HAMILTON SH, EDGELL ET, REVICKI DA, BREIER A. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol 2000;15:245-255.
47. LEWIS D. Controlled release of bioactive agents from lactide/glycolide polymers. In: CHASIN M, LANGER R, eds. Biodegradable polymers as drug delivery systems. New York: Marcel Dekker, 1990: 1-41.
48. KANE JM, EERDEKENS M, LINDENMAYER JP, KEITH S, LESEM M, KARCHER K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotics. Am J Psychiatry 2003;160:1125-1132.
49. EERDEKENS M, RASMUSSEN A, VERMEULEN A, LOWENTHAL PEER V. Kinetics and safety of a novel long-acting risperidone formulation. Int J Neuropsychopharmacol 2000;3(Suppl. 1):135.
50. FLEISCHHACKER WW, EERDEKENS M, KARCHER K et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12 month evaluation of the first long-acting 2nd generation antipsychotic. J Clin Psychiatry 2003;64:1250-1257.
51. GHARABAWI G, LASSER R, BOSSIE C, ZHU Y, BALDESSARINI R. Enhanced one-year outcomes with three doses of long-acting injectable risperidone in 336 chronically psychotic, stable patients switched from oral risperidone. Presented as a poster at the American College of Neuropsychopharmacology 41st Annual Meeting, December 8-12, 2002, San Juan, Puerto Rico. Poster No 175.
52. LASSER R, BOSSIE C, GHARABAWI G, TURNER M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 2004;19:219-225.
53. VAN OS J, BOSSIE C, LASSER R. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int Clin Psychopharmacol 2004;19:229-232.
54. NASRALLAH H, DUCHESNE I, MEHNERT A, JANAGAP C. Long-acting risperidone injection improves quality of life. American College of Neuropsychopharmacology scientific abstracts, American College of Neuropsychopharmacology 41st Annual Meeting, December 8-12, 2002, San Juan, Puerto Rico.
55. FREYBERGER HJ, EERDEKENS M, DUCHESNE I, MEHNERT A, RABINOWITZ J. Patient satisfaction with their medication during long-term treatment with long-acting risperidone injection. Int J Neuropsychopharmacol 2002;5(Suppl. 1):S189.
56. REMINGTON G, DEVOS E, EERDEKENS M, DUCHESNE I, LEAL A, MEHNERT A. Treatment with long-acting risperidone injection reduces healthcare resource use. Int J Neuropsychopharmacol 2002;5(Suppl. 1):S189.